AUSTIN, Texas, Aug. 31, 2017 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML) will launch Ovarian Cancer Awareness Month by ringing the opening bell on Friday, September 1, joined by the New York City chapter of the National Ovarian Cancer Coalition. In the U.S. this year, there is estimated to be approximately 22,000 cases of ovarian cancer and more than 14,000 deaths resulting from this disease.
In addition to bringing public awareness to the symptoms, plight, and aiding clinicians in the risk assessment of ovarian cancer, Vermillion has recently achieved a significant milestone as more than 100,000 women have had their ovarian cancer risk assessed with OVA1. OVA1 is an FDA and guideline supported biomarker test that assesses preoperative risk of ovarian cancer for all ages, stages, and cancer types. There is no other technology equal to OVA1 currently available to women today.
"Hitting the 100,000 OVA1 mark is a major milestone in our goal of becoming the 'New Risk Assessment Tool' versus the standard of care, CA125, in assessing risk of ovarian cancer," stated Valerie Palmieri, President and CEO of Vermillion. "Marking this milestone by participating in the Opening Bell Ceremony of the Nasdaq National Market puts a spotlight on the cause, and widens the audience for this serious disease which affects thousands of women every year. This milestone demonstrates an important step towards the adoption of a new class of technology, bioinformatics coupled with diagnostics, to deliver a more comprehensive assessment of ovarian cancer risk worldwide."
Throughout the month of September, ovarian cancer patients, survivors, as well as the general public, are encouraged to wear the color 'teal' to raise awareness of Ovarian Cancer and to educate women regarding its symptoms.
To become aware of the symptoms and take an Ovarian Cancer Risk Assessment quiz, visit quiz.aspiralab.com.
Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. Vermillion, along with its prestigious scientific collaborators, discovers, develops and delivers innovative diagnostic and technology tools that help women with serious diseases. The company's initial in vitro diagnostic test, OVA1® (MIA), was the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, and represented a new class of software-based liquid biopsy in vitro diagnostics. In March 2016, Vermillion received FDA clearance for Overa™, a second generation OVA1 (MIA2G) test with significantly improved specificity and ease of use. For additional information, including published clinical trials, visit www.vermillion.com.